-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
DENV-IN-6
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/denv-in-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | DENV-IN-6 is a potent DENV (I-IV) inhibitor with EC50s of 17.5, 13.20, 6.8 and 11.41 μM for the inhibition of DENV (I-IV) replication, respectively. DENV-IN-6 also exhibits activity of anti-HIV-1IIIB (EC50=0.0181 µM; CC50=64.92 µM). |
Product Information
| Synonyms | DENV-IN-6|SCHEMBL21346533|CS-0434018|2-[[4-chloro-5-(4-fluorophenyl)-1H-pyrazol-3-yl]methylsulfanyl]-4-(cyclohexylmethyl)-5-ethyl-1H-pyrimidin-6-one |
| Molecular Weight | 461 |
| Molecular Formula | C23H26ClFN4OS |
| Canonical SMILES | CCC1=C(N=C(NC1=O)SCC2=C(C(=NN2)C3=CC=C(C=C3)F)Cl)CC4CCCCC4 |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 704 |
| Exact Mass | 460.1499885 |
| In Vitro | DENV-IN-6 (compound 4a) (0.04, 0.2, 1, 5, 25 μM; 5 days) shows inhibitory effect on replication of DENV (I-IV) in a dose-dependent manner (EC50s=17.5, 13.20, 6.8 and 11.41 μM, respectively). DENV-IN-6 (25 μM; 5 days) shows low toxic to Vero cells (CC50>200 μM) and exhibits stronger inhibitory effect on DENV-III than on DENV-I, II, IV with a TI value is greater than 29.41. |
| Target | HIV (IIIB) |
| XLogP3-AA | 6.2 |